Activation of the Mitogen-activated Protein Kinases Erk1/2 by Erythropoietin Receptor via a Gi Protein beta gamma -Subunit-initiated Pathway*

Christine Guillard, Stany Chrétien, Anne-Sophie Pelus, Françoise Porteu, Odile Muller, Patrick Mayeux, and Véronique DuprezDagger

From the Department of Hematology, Institut Cochin, INSERM U567, CNRS UMR 8104, Université René Descartes, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France

Received for publication, August 29, 2002, and in revised form, January 6, 2003

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We have recently shown that a heterotrimeric Gi protein is coupled to the erythropoietin (Epo) receptor. The Gi protein constitutively associates in its heterotrimeric form with the intracellular domain of Epo receptor (EpoR). After Epo stimulation Gi is released from the receptor and activated. In the present study we have investigated the functional role of the heterotrimeric Gi protein bound to EpoR. In Chinese hamster ovary cells expressing EpoR, the Gi inhibitor pertussis toxin blocked mitogen-activated protein kinase (MAPK) Erk1/2 activation induced by Epo. Epo-dependent MAPK activation was also sensitive to the Gbeta gamma competitive inhibitor beta ARK1-ct (C-terminal fragment of the beta -adrenergic receptor kinase), to the Ras dominant negative mutant RasN17, and to the phosphoinositide 3-kinase (PI3K) inhibitor LY 294002. A region of 7 amino acids (469-475) in the C-terminal end of EpoR was shown to be required for Gi binding to EpoR in vivo. Deletion of this region in EpoR abolished both MAPK and PI3K activation in response to Epo. We conclude that in Chinese hamster ovary cells, Epo activates MAPK via a novel pathway dependant on Gi association to EpoR, Gbeta gamma subunit, Ras, and PI3K. The tyrosine kinase Jak2 also contributes to this new pathway, more likely downstream of beta gamma and upstream of Ras and PI3K. This pathway is similar to the best characterized pathway used by seven transmembrane receptors coupled to Gi to activate MAPK and may cooperate with other described Epo-dependent MAPK activation pathways in hematopoietic cells.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The survival, proliferation, and differentiation of erythroid progenitor cells is regulated by erythropoietin (Epo)1 (1). The binding of Epo to its receptor (EpoR), a member of the cytokine receptor superfamily, initiates a signal cascade that includes activation of the Jak2 tyrosine kinase, phosphorylation of the EpoR (2-4), activation of PI3K (5-7), STAT5 (8), and stimulation of the Ras/Raf/mitogen-activated protein kinases (MAPK) pathway (9-13). The EpoR recruits several SH2-containing proteins through its intracellular phosphorylated tyrosines as well as adaptor molecules (for review, see Ref. 14). We previously developed an expression cloning strategy to characterize new proteins implicated in EpoR signaling. The strategy was based on the reactivity of such components with antibodies produced against proteins reactive with anti-phosphotyrosine (Tyr(P)) antibodies, isolated from the Epo-stimulated hematopoietic cell line UT7. This led us to isolate a cDNA encoding Gbeta 2, the beta 2 subunit of the heterotrimeric GTP-binding proteins, and to demonstrate that an heterotrimeric Gi protein is constitutively associated with EpoR in hematopoietic cell lines as well as in normal erythroid progenitor cells. The Gi-EpoR interaction occurs through the C-terminal end of the cytoplasmic domain of the receptor. After Epo activation the Gi protein is activated and released from the receptor, most likely with the concomitant dissociation of Gi alpha  and beta gamma subunits (15).

Defined signal functions of Gi include inhibition of adenylyl cyclase, regulation of phospholipase Cbeta , and activation of K+ channels (16). G proteins such as Gq and Gi also regulate cell growth and differentiation through the stimulation of a large number of complex cascades, leading to the activation of MAPKs. Agonist stimulation of seven transmembrane-spanning G protein-coupled receptors (GPCRs) leads to the exchange of GDP for GTP on the alpha  subunit of the heterotrimeric G protein and the subsequent dissociation of the alpha -GTP and beta gamma subunits. Although the main functional properties of G proteins were initially thought to be essentially determined by the identity of the alpha  subunit, beta gamma complexes also regulate a number of effectors. The mechanisms of the Erk1/2 MAPK activation by GPCR has been explored in cell lines that are readily transfected, such as COS-7 cells. The best characterized and probably the main pathway used by GPCR to activate MAPK via the pertussis toxin (PT)-sensitive Gi protein depends on the release of free Gbeta gamma subunits acting on a Ras-dependent pathway (17-19). MAPK activation is initiated by the Gbeta gamma -mediated tyrosine phosphorylation of Shc and proceeds through a Shc/Grb2/Sos pathway common to both GPCR and tyrosine kinase receptors (19). PI3K activity also participates in Gbeta gamma -mediated MAPK activation upstream of Ras (20-22) or by stimulating MEK phosphorylation (23). Gi may also regulate MAPK activation through alpha  subunits. Indeed, activating mutations have been identified in the Galpha i2 gene, referred to as gip2 (24, 25), and MAPK is constitutively activated in gip2-transformed fibroblasts (24).

The MAPKs Erk1/2 play important role in Epo-induced proliferation, differentiation, and apoptosis (26-28). In hematopoietic cells Epo activates the Ras/Raf/MEK/MAPK pathway by recruitment of Grb2 either directly or indirectly via adaptor molecules such as Shc (29, 30) or SHP-2 (31, 32). This interaction allows the guanine nucleotide release factor Sos, constitutively bound to Grb2, to convert Ras to an active GTP-bound form. Furthermore, C3G, an other guanine nucleotide exchange factor, through its interaction with CrkL, has also been found participating in Epo-mediated MAPK signaling pathway via Ras (33) and Rac (34). PI3K and protein kinase C have also been implicated in Raf/MAPK activation by Epo (35, 36).

Our demonstration that heterotrimeric Gi proteins associate with EpoR and that receptor activation leads to the activation and dissociation of Gi from the receptor led us to investigate the downstream targets of Gi. We considered the possibility that Epo may activate MAPK via the Gi protein bound to EpoR-like seven-transmembrane receptors. In this study, we characterized a new Epo-activated MAPK pathway dependent on Gi. This pathway, similar to the best characterized MAPK pathway used by GPCR coupled to Gi, is the main pathway for Epo-dependent MAPK activation in CHO cells. It proceeds through the beta gamma subunit of the Gi bound to EpoR and involves the activation of Jak2, Ras, PI3K, and MEK. Our data also demonstrate that Gi plays a crucial role for Epo-induced PI3K activation in CHO cells.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Purified recombinant human Epo (specific activity 120,000 units/mg) was a kind gift of Dr. M. Brandt (Roche Molecular Biochemicals). Rabbit polyclonal antibodies against Gbeta (M-14), Akt 1/2 (H-136), and Erk (C-16) were purchased from Santa Cruz Biotechnology. Anti-Jak2 antibodies (06-255) were supplied from Upstate Biotechnology. Polyclonal antibodies specific to the phospho-forms of Erk (Thr-202/Tyr-204) and Akt (Ser-473) were supplied from Cell Signaling Technology. Anti-phosphotyrosine (anti-Tyr(P)) monoclonal antibodies 4G10 and PY72 were produced from hybridoma cell lines kindly provided by B. Drucker and B. Sefton. Anti-MalE antiserum and anti-EpoR antiserum against a fusion protein between glutathione S-transferase and the cytoplasmic portion of the human EpoR were described previously (37). Anti-HA peptide monoclonal antibody was purchased from Roche Molecular Biochemicals. Peroxidase-conjugated anti-rabbit antibodies were purchased from Amersham Biosciences and Cell Signaling Technology. MEK1 inhibitor PD98059 was supplied from New England Biolabs, PI3K inhibitor LY 294002 and PMA were from Sigma, pertussis toxin was from Alexis, and protease inhibitors were from Roche Molecular Biochemicals. Amylose resin was supplied from Biolabs. The minigene encoding the C terminus of bovine beta ARK1 (beta ARK-ct) (38) was kindly provided by R. Jockers at Institut Cochin, Paris, France. The expression plasmid pcDNA3/HA-RasN17 was a gift from A. Eychène and the pXM/EpoR-W282R from J. Ihle.

Plasmid Constructs-- Different constructs of murine EpoR cytoplasmic regions (Leu-433-Pro-459, Gly-458-Ser-483, Gly-458-Pro-470, Glu-465-Pro-477) were obtained by PCR and subcloned in-frame with the MalE protein.

The murine EpoR mutant -41 was described previously (15). To generate the Delta V-L EpoR mutant lacking residues Val-469 to Leu-475 within the intracellular domain, mutation was introduced into the full-length EpoR by PCR. The PCR product was digested with HindIII/XbaI and subcloned into the same restriction sites of a modified pCDNA3 expression vector (15). The fidelity of all constructs was confirmed by sequencing.

Transfections-- Stable transfectants of FDCP-1 myeloid cell line expressing the wild type and mutated forms of EpoR were obtained by electroporation, as previously described (8). CHO cells were transfected with expression plasmids coding for full-length EpoR, Delta V-L, or W282R EpoR mutants using LipofectAMINE PlusTM Reagent (Invitrogen) according to the manufacturer's instruction, selected with 20 µg/ml puromycin, and cloned by limiting dilution. EpoR expression was determined using immunoblot analysis of cellular extracts and 125I-Epo binding on whole cells. Cell lines expressing a similar number of 125I-Epo binding sites of either wild type or mutated receptors were selected for the study. Transient transfections of CHO cells were carried out by the same methodology when 80% confluence was reached using 1 µg of plasmid/well (10 cm2), and 24 h post-transfection the cells were harvested and used in experiments as described. LipofectAMINE transfection of CHO cells consistently resulted in transfection efficiencies greater than 60% (data not shown).

Cell Culture and Treatments-- The human erythroleukemic cell line UT7 was maintained in alpha -minimal essential medium supplemented with 5% fetal bovine serum, penicillin, streptomycin, 2 mM L-glutamine, and 2 units/ml Epo. FDCP-1 myeloid cells expressing EpoR were grown in alpha -minimal essential medium supplemented with 5% fetal bovine serum and 2 units/ml Epo. The cells were starved of Epo by replacing Epo with 3% WEHI-conditioned medium as a source of interleukin 3 1-2 days before use in the experiments. CHO cells were grown in Dulbecco's minimal essential medium/nut mix F-12 (Ham's) medium supplemented with 7% fetal bovine serum. Before stimulation, cells were washed and serum-starved 3-4 h or overnight when indicated by incubation in Ham's medium in the presence of 0.4% bovine serum albumin. The cells were stimulated with 10 units/ml Epo or 10 ng/ml PMA. In some experiments PD98059 (30 µM) or LY 294002 (50 µM) were added 30 or 15 min, respectively, before stimulation, and pertussis toxin (50 ng/ml) and PMA (0.6 µg/ml) were added 16 h before stimulation.

Immunoprecipitations and MalE Pull-down Assays-- Cells (1 × 107) were washed in phosphate-buffered saline containing 50 µM Na3VO4 and lysed on ice in 150 mM NaCl, 50 mM Tris-HCL (pH 7.5), 1% Brij 98, 1 mM Na3VO4, 2 mM EGTA, 10% glycerol, and protease inhibitors (lysis buffer). Insoluble material was removed by centrifugation at 15,000 × g for 10 min at 4 °C. For immunoprecipitation, lysates were incubated with anti-EpoR antiserum 1/250 for 1 h at 4 °C. Protein G-Sepharose (Amersham Biosciences) was added, and the incubation was pursued for 1 h at 4 °C with rotation. Samples were washed 3 times with lysis buffer and 2 times with 150 mM NaCl, 50 mM Tris-HCL (pH 7.5), 0.1% Brij 98, 1 mM Na3VO4. For MalE fusion protein pull-down assays, lysates were incubated with 5 µg of MalE fusion protein prebound to 20 µl of amylose resin beads for 2 h at 4 °C with rotation. Then, beads were collected and processed as described above for immunoprecipitation. Proteins were eluted by boiling in SDS sample buffer, resolved on SDS-PAGE, and subjected to immunoblotting as described previously (3, 39).

Determination of MAPK and Akt Activation-- Erk and Akt activation were studied using phospho-specific antibodies. Cells lysates were prepared as described above using lysis buffer containing 1% Nonidet P-40. The protein content was normalized by the micro-BCA assay (Pierce), and equal amounts of proteins (10 to 50 µg) were separated by 10% SDS-PAGE. Proteins were transferred to nitrocellulose membranes and analyzed in immunoblot.

ADP-ribosylation Assay-- To detect Galpha i its ADP-ribosylation was followed by measuring incorporation of [32P]ADP-ribose in the presence of pertussis toxin in vitro as previously described (15).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Identification of the Sequence in the EpoR Required for Gi Binding-- In a previous report we demonstrated that constitutive association between heterotrimeric Gi protein and the EpoR occurred through the C-terminal end of the receptor (15). To characterize more precisely the EpoR domain involved in Gi binding, we first generated recombinant fusion proteins between MalE and various EpoR sequences contained in this region (Fig. 1A). Fusion proteins were incubated with UT7 cell lysates, and bound proteins were analyzed by immunoblotting with anti-Gbeta antibodies (Fig. 1B). Recombinant fusion protein containing the EpoR amino acids 458-483 allowed Gbeta binding in vitro, in agreement with previous data obtained in vivo using EpoR mutants (15). A similar binding was detected with the MalE-EpoR fusion peptide 465-477, whereas Gbeta did not bind to EpoR peptides 433-459 and 458-470. Western blotting with anti-MalE antibody showed that the amounts of recombinant proteins bound to amylose resin used in the pull-down assays were similar. These results indicate that amino acids 465-477 are sufficient to bind Gbeta in vitro. This region does not include tyrosine residues, which fits well with the constitutive binding of Gi to EpoR (15).


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 1.   Characterization of EpoR domain coupling to Gi. A, schematic representation of EpoR mutants and peptides used in this study. Top, truncation (-41) and deletion (Delta V469-L475) EpoR mutants expressed into cells. Bottom, EpoR peptides used as MalE fusion proteins for in vitro binding studies. B, association of EpoR intracellular domain with Gbeta in vitro. Lysates from UT7 cells were incubated with immobilized MalE-EpoR fusion proteins. Bound proteins were resolved by SDS-PAGE, transferred to nitrocellulose membrane, and analyzed by anti-Gbeta and anti-MalE immunoblotting. C, FDCP-1 cells expressing no EpoR (-), wild type EpoR (WT), or the indicated EpoR mutants were lysed with 1% Brij 98, and immunoprecipitation was performed with anti-EpoR antiserum. Immunoprecipitates were subjected to ADP-ribosylation as described under "Experimental Procedures." The proteins were separated by SDS-PAGE and transferred to nitrocellulose membrane. Galpha i was visualized by autoradiography, and Jak2 was identified by immunoblotting.

To evaluate the role of the identified sequence (465-477) in vivo we wished to delete this sequence within the EpoR. To avoid perturbation of receptor structure and particularly of Tyr-464 and Tyr-479 located in the vicinity of Gi binding region, we constructed an EpoR mutant deleting a shorter region encompassing amino acids 469-475 (Delta V-L). The EpoR expressed in FDCP-1 cells was immunoprecipitated from cell lysates, and Galpha i associated with EpoR was detected by in vitro ADP-ribosylation assay (Fig. 1C). In cells transfected with full-length mouse EpoR, Galpha i was coprecipitated with anti-EpoR antibodies. However, Galpha i was not precipitated with EpoR when mutants -41 (15) or Delta V-L were expressed. The absence of Gi binding to the EpoR in cells expressing the Delta V-L mutant is unlikely to be due to a general signaling defect of the mutated receptor since the receptor kept the ability to bind the tyrosine kinase Jak2 (Fig. 1C). These results indicate that the sequence V469PDSEPL475 located in the C-terminal domain of the EpoR is necessary for Gi/EpoR association in vivo. This region does not bind any known EpoR effector.

Epo Stimulates a Gi-dependent Erk1/2 Activation Pathway in CHO Cells Expressing the EpoR-- A number of receptors that couple to heterotrimeric G proteins, including Gi-coupled receptors, have been shown to stimulate MAPK activation (17, 18, 38). Therefore, we explored the possibility that Gi may participate in MAPK activation after Epo stimulation. The sensitivity of MAPK activation to the Gi inhibitor, pertussis toxin, was first examined in hematopoietic cell lines expressing an endogenous or exogenous EpoR as well as in normal human erythroid progenitor cells. A weak and inconstant inhibition of Epo-induced MAPK phosphorylation was observed with these cells (data not shown). We previously observed that Epo induced a stronger G protein activation in cell membranes isolated from epithelial CHO cells expressing EpoR than in UT7 hematopoietic cell line (15). This led us to hypothesis that a Gi-dependent Epo-activated MAPK pathway may be more easily detected in these cells.

The role of Gi in the activation of Erk1/2 by Epo was investigated in CHO cells stably transfected with the full-length EpoR cDNA (CHO-ER WT). Cells were stimulated with Epo for various times, and the lysates were subjected to immunoblotting with phospho-specific anti-Erk antibodies as shown in Fig. 2. Epo induced a transient Erk1/2 activation. Preincubation of the cells with 50 ng/ml pertussis toxin overnight completely inhibited Epo-induced Erk activation. Total Erk content was unchanged under all conditions as shown by immunoblotting with anti-Erk antibodies recognizing both the phosphorylated and the unphosphorylated forms of Erk 1 and 2. Toxin treatment had no effect on cell viability (data not shown). These results establish a role for a pertussis toxin-sensitive G protein in Epo-induced Erk activation and show that a Gi-dependent pathway is the main pathway used by Epo to activate MAPK in CHO cells.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 2.   Pertussis toxin treatment inhibits the phosphorylation of endogenous MAPK following stimulation of EpoR with Epo. CHO-ER cells expressing WT EpoR were preincubated overnight at 37 °C in the absence (PT-) or presence (PT+) of 50 ng/ml pertussis toxin. Subsequently the cells were stimulated with 10 units/ml Epo for the indicated times and lysed. The soluble fraction was separated by SDS-PAGE and transferred to nitrocellulose membranes. Determination of MAPK activity was assessed by immunoblotting with phospho-specific anti-Erk antibodies (anti-pErk). The same blot was also probed with antibodies to Erk1/2 (anti-Erk) to confirm that equal amounts of enzyme were present in each lane.

To ascertain the functional significance of the Gi-EpoR interaction on MAPK activation we studied the effect of disrupting it. When stably expressed in CHO cells the EpoR Delta V-L mutant, which is unable to associate with Gi (Fig. 1C), could not activate Erk after Epo stimulation (Fig. 3A). In contrast, PMA treatment led to MAPK activation, showing that these cells retained the ability to activate Erk. To evaluate if the Delta V-L deletion would perturb early events of EpoR activation, Jak2 was immunoprecipitated and subjected to analysis using anti-phosphotyrosine antibodies. Fig. 3B illustrates that the EpoR Delta V-L mutant had the ability to associate with the Jak2 tyrosine kinase and that both proteins became phosphorylated after Epo stimulation. Indeed, when Jak2 was immunoprecipitated, the phosphorylated forms of Jak2 and EpoR were detected in immune complexes isolated from cells expressing EpoR WT as well as EpoR Delta V-L. Thus, the Delta V-L deletion has no general effect on Epo signal transduction. Tyrosines located in the vicinity of the Val-469-Leu-475 region constitute potential binding sites for components implicated in Epo-dependent MAPK activation such as CrkL (40) and Grb2 (32) for Tyr-460 and Tyr-464, respectively. Therefore, we wanted to determine whether the Delta V-L deletion did not alter the phosphorylation of these residues and their ability to bind their effectors. After Epo activation, phosphorylated EpoR Delta V-L bound GST-CrkL and GST-Grb2 as efficiently as phosphorylated EPOR WT did (data not shown). This strongly suggests that the absence of MAPK activation in EpoR Delta V-L is due to a defect in Gi binding and not to a perturbation of the phosphorylation of proximal tyrosine residues. Altogether, these data show that the EpoR region that couples Gi to EpoR is required for Epo-induced Erk activation in CHO cells and confirm the results obtained with pertussis toxin treatment.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 3.   MAPK phosphorylation requires the integrity of Gi binding domain of the EpoR. CHO-ER cells expressing WT EpoR or mutant Delta V-L EpoR were serum-depleted and stimulated with 10 units/ml Epo or 10 ng/ml PMA for the indicated time (A) or for 5 min with Epo (B) and lysed. A, phosphorylated Erk and total Erk were detected by immunoblotting as in Fig. 2. B, Jak2 was immunoprecipitated, and phosphorylated Jak2 and EpoR were identified by immunoblotting with anti-phosphotyrosine (pTyr) antibodies.

Epo-mediated MAPK Activation in CHO-ER Cells Is Dependent on Gbeta gamma -- Given the sensitivity of Epo action to pertussis toxin, we first examined whether Epo-mediated Erk1/2 activation may be secondary to inhibition of adenylyl cyclase by Gi. Indeed, in some cells a rise in cAMP has been shown to inhibit the Ras/MAPK pathway at the level of Ras/Raf interaction (41). Therefore, a Gi-mediated fall in cAMP level may relieve Raf inhibition by protein kinase A and positively regulate MAPK. Pretreatment of CHO-ER WT cells with the cell-permeable cAMP derivative dibutyryl-cAMP, which mimics the effect of cAMP, failed to prevent Epo-induced MAPK activation (data not shown). This suggests that MAPK activation does not proceed through alpha i-mediated inhibition of adenylyl cyclase.

beta gamma subunits derived from PT-sensitive heterotrimeric G proteins were shown to mediate Ras-dependent MAPK activation (17, 18, 42). MAPK activation through Gi-coupled receptors such as the alpha 2A-adrenergic receptor and the lysophosphatidic acid receptor is sensitive to inhibition by the C-terminal fragment of the beta -adrenergic receptor kinase (beta ARK1-ct). beta ARK1-ct interacts with free beta gamma and acts as a competitive inhibitor of Gbeta gamma -mediated signals but does not affect Galpha i-mediated signaling, allowing distinguishing between alpha i and beta gamma pathways (38). To determine whether the PT-sensitive phosphorylation of Erk1/2 stimulated by Epo was mediated by Gbeta gamma , we studied the effect of Epo on CHO-ER WT cells transiently transfected with the beta ARK1-ct peptide. As shown in Fig. 4A phosphorylation of endogenous Erk1/2 following Epo stimulation was significantly reduced compared with cells transfected with control plasmid, although the total Erk amount was not modified. We conclude that Epo-induced MAPK activation in CHO-ER cells occurs through the release of beta gamma subunits of heterotrimeric Gi protein.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 4.   The phosphorylation of endogenous Erk-1/2 after stimulation of EpoR with Epo is dependent on beta gamma , MEK, and Jak2. CHO-ER WT cells were transfected with the minigene encoding the C terminus of bovine beta ARK1 (beta ARK-ct) or empty vector. 24 h later the cells were serum-starved for 4 h (A). CHO-ER WT cells were serum-starved and preincubated (+) or not (-) with 30 mM PD98059 for 30 min (B). CHO-ER cells expressing WT EpoR or mutant W282R EpoR were serum-depleted (C). Subsequently the cells were stimulated with 10 units/ml Epo for 5 min and lysed. The soluble fraction was analyzed by anti-phospho-Erk and anti-Erk immunoblotting.

Epo-mediated MAPK Activation in CHO-ER Cells Is Dependent on JAK2, Ras, and MEK-- To determine whether Epo-induced JAK2 tyrosine kinase activation was required for MAPK activation, the EpoR mutant (W282R) defective in JAK2 binding and kinase activation (43) was stably expressed in CHO cells. In cells expressing the EpoR W282R mutant, Epo-induced MAPK activation was lost (Fig. 4C). Thus, JAK2 activation is required for MAPK activation in these cells. The requirement for MEK kinase, an upstream activator of MAPK, was also evaluated using the MEK inhibitor PD98059. As shown in Fig. 4B, Epo-induced MAPK activation was abolished when the cells were pretreated with the MEK inhibitor before Epo stimulation.

Protein kinase C is activated by Epo and may be implicated in MAPK activation by Epo (36) and also by Gi coupled to classical GPCR (44). We examined whether protein kinase C might contribute to Epo-induced MAPK activation in CHO-ER WT cells. Down-regulation of protein kinase C induced by prolonged exposure of cells to PMA inhibited MAPK activation in response to PMA but not to Epo (Fig. 5B). Therefore, Epo-stimulated MAPK activation is independent of a PMA-sensitive protein kinase C. The best characterized pathway used by Gi-coupled receptors to activate MAPK requires p21ras activity (45, 46). To investigate the role of p21ras in Epo-mediated MAPK activation in CHO-ER WT cells, the effects of the dominant negative mutant RasN17 on EpoR-stimulated MAPK activation was assessed. As shown in Fig. 5A, RasN17 expression inhibited Epo-stimulated phosphorylation of Erk. In contrast RasN17 expression did not alter the level of Epo-stimulated Jak2 tyrosine phosphorylation (see Fig. 8A). Taken together these results suggest that in CHO cells expressing EpoR, Epo acts through Jak2 to activate Ras and Erk1/2 MAPK.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 5.   Contribution of Ras and not protein kinase C to Epo-dependent MAPK activation. CHO-ER WT cells were transfected with various amounts of HA-RasN17 as indicated. The total plasmid DNA amount was kept constant by adding pCDNA empty vector. 24 h later the cells were serum-starved for 4 h and stimulated with Epo(+) or not (-) for 5 min (A). CHO-ER WT cells were serum-depleted and preincubated or not for 16 h with 0.6 µg/ml PMA followed by stimulation with 10 units/ml Epo or 10 ng/ml PMA for 5 min (B). Erk activation was assessed by immunoblotting with phosphospecific anti-Erk antibodies. The same blot was also probed with anti-Erk antibodies.

Functional Role of PI3K in Gi-dependent Epo-induced MAPK Activation-- PI3K has been implicated in the beta gamma -dependent activation of MAPK by Gi-coupled receptors (21, 22). Therefore, we next examined whether PI3K also contributed to Epo-induced MAPK activation in CHO-ER WT cells. Pretreatment of the cells with LY 294002, a PI3K inhibitor, blocked Epo-stimulated activation of the PI3K, as detected by antibodies specific to the phospho-form of the PI3K effector Akt (Fig. 6A). LY 294002 also strongly decreased the activation of MAPK by Epo without modification of the total Erk content (Fig. 6A). These data show that PI3K contributes to Epo-dependent MAPK activation in CHO-ER WT cells. Because MAPK activation is essentially Gi-dependent in these cells, they also suggest that PI3K is a component of the Gi-dependent Erk1/2 pathway. To determine whether Gi is required for PI3K activation, Epo-induced Akt phosphorylation was compared in CHO-ER WT expressing the full-length receptor or the Delta V-L mutant defective in Gi interaction and MAPK activation. As shown in Fig. 7A the deletion mutant had lost the ability to activate Akt in response to Epo. As expected, expression of the beta gamma competitor beta ARK1-ct also inhibited Akt phosphorylation by EpoR WT (Fig. 7B).


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 6.   PI3K is necessary for MAPK phosphorylation. Inhibition of MAPK activation with PI3K inhibitor. CHO-ER WT cells were serum-starved and preincubated (+) or not (-) with 50 µM LY 294002 for 15 min. Subsequently the cells were stimulated with 10 units/ml Epo for the indicated time and lysed. Erk activation was assessed by immunoblotting with phosphospecific anti-Erk antibodies (anti-pErk) and PI3K activation by immunoblotting with phosphospecific anti-Akt antibodies (anti-pAkt). The same blot was probed with antibodies to Erk1/2 (anti-Erk) and Akt (anti-Akt) to confirm that equal amounts of enzymes were present in each lane.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 7.   PI3K activation requires the integrity of the Gi binding domain in EpoR and beta gamma . A, PI3K activation requires the integrity of Gi binding domain of the EpoR. CHO-ER cells expressing WT EpoR or mutant Delta V-L EpoR were serum-depleted and stimulated with Epo for the indicated time. B, PI3K activation is dependent on beta gamma . CHO-ER WT cells were transfected with the minigene encoding the C terminus of bovine beta ARK1 (beta ARK-ct) or empty vector. 24 h later the cells were serum-starved for 4 h, stimulated with 10 units/ml Epo for 5 min, and lysed. Phosphorylated Akt and total Akt present in cell lysates were detected by immunoblotting.

The requirement for Ras and Jak2 in PI3K activation was then evaluated. Expression of RasN17 in CHO-ER WT prevented Akt activation after Epo stimulation (Fig. 8A). Furthermore the EpoR mutant defective in Jak2 binding and activation (W282R) failed to activate Akt (Fig. 8B), showing that Jak2 tyrosine kinase and Ras are upstream of PI3K activation. Taken together, these data demonstrate that the beta gamma subunit of Gi plays a crucial role in Epo-mediated PI3K activation and that PI3K is a component of the Epo-activated Gi-dependent MAPK activation pathway downstream of Jak2 and Ras.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 8.   PI3K activation is dependent on Jak2 and Ras and Jak2 activation is independent on Ras. A, Ras is required for PI3K activation but not for Jak2 activation. CHO-ER cells WT were transfected with 0.75 µg of HA-RasN17 or empty vector. 24 h later the cells were serum-starved for 4 h, stimulated with Epo (+) or not (-) for 5 min, and lysed. Jak2 was immunoprecipitated (IP), and phosphorylated Jak2 was identified by immunoblotting with anti-phosphotyrosine (PY). Total Jak2 in immunoprecipitates was also determined by anti-Jak2 antibodies (top). Phosphorylated Akt (pAkt), total Akt, phosphorylated Erk (pErk), total Erk, and HA-RasN17 present in cell lysates were visualized by immunoblotting as indicated (bottom). B, Jak2 is required for PI3K activation. CHO-ER cells expressing WT EpoR or EpoR mutant W282R were serum-depleted, stimulated with Epo (+) or not (-) for 5 min, and lysed. Phosphorylated and total Akt, phosphorylated EpoR (REpo), and phosphorylated and total Erk present in cell lysates were analyzed by immunoblotting.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this study we showed that Epo can activate the Erk1/2 MAPK pathway via a new Gi-dependent pathway sensitive to pertussis toxin. The activation of MAPK by EpoR is mediated by the beta gamma subunits and not the alpha  subunit of Gi. Indeed, MAPK phosphorylation in response to Epo was inhibited by the coexpressed beta gamma competitor beta ARK1 polypeptide. The marked inhibition observed with these agents suggests that the beta gamma pathway is the main pathway for Epo-mediated MAPK activation in CHO cells expressing the EpoR. Classical G protein-coupled receptors, (17, 18, 42, 47) and some tyrosine kinase receptors, such as the receptors for insulin-like growth factor-1 and fibroblast growth factor (48, 49), activate Erk1/2 through mechanisms involving beta gamma subunits derived from pertussis toxin-sensitive G proteins in neuronal cells, epithelial cells, and fibroblasts. To our knowledge our study represents the first demonstration of a functional role of Gbeta gamma subunits in cytokine receptor signaling. Signaling from Gi to MAPK more often involves beta gamma subunits of heterotrimeric G proteins acting on a Ras-dependent pathway (42, 45). Likewise, Epo-induced MAPK activation is consistent with this general mechanism, since it is dependent on Ras as shown by its inhibition by a dominant negative mutant of Ras (RasN17).

Our data also demonstrate that PI3K activation by Epo is dependent on Gi beta gamma subunits and is required for Erk activation downstream of Ras in CHO cells. Indeed (i) Epo-induced Akt phosphorylation was inhibited by expression of the beta ARK1-ct or RasN17, (ii) the EpoR mutant defective in Gi binding lost the ability to phosphorylate both Erk1/2 and the PI3K effector Akt, and (iii) the PI3K inhibitor LY 294002 inhibited MAPK activation by Epo. Because MAPK activation by Epo is mainly Gi-dependent in CHO cells, these data also suggest that the beta gamma -dependent PI3K activation by Epo is upstream of MAPK and does not form a separate pathway. Similarly, PI3K was shown to be involved in Gi-dependent MAPK activation by platelet-derived growth factor in airway smooth muscle cells (50, 51). PI3K has a critical role linking G protein-coupled receptors and Gbeta gamma to the MAPK-signaling pathway. Different mechanisms could be implicated in this process. Previous reports implicate PI3Kalpha or -beta (21, 52) and PI3Kgamma (22) in the activation of MAPK by classical Gi-coupled receptors upstream of Sos and Ras activation (21, 22). PI3Kgamma could represent the link between beta gamma and a downstream tyrosine kinase required for Ras-dependent MAPK activation (22). However, this mechanism does not apply here since we show that PI3K is downstream of Ras. PI3K could also contribute to the Gi-initiated MAPK pathway without Ras requirement (23).

Several candidate tyrosine kinases have been proposed as intermediates between beta gamma and Ras/MAPK activation including c-Src family kinases (53), Syk (54), and Pyk2 (55). Alternatively, Gi can activate MAPK through transactivation of the epidermal growth factor tyrosine kinase receptor (56). Activated c-Src or epidermal growth factor receptor mediate Ras/MAPK activation through tyrosine phosphorylation of Shc and its subsequent association with Grb2 (53, 56). An essential component for Gi-dependent Erk activation by EpoR is the tyrosine kinase Jak2. Indeed CHO cells expressing the W282R EpoR mutant defective in Jak2 binding and activation have lost the ability to activate MAPK. Epo-induced PI3K activation was also inhibited in these cells, suggesting that PI3K is located downstream of Jak2 in this pathway. Ras is probably positioned downstream of Jak2, since RasN17 expression had no effect on Jak2 phosphorylation. Jak2 contribution to MAPK activation is independent of Gi binding to EpoR and subsequent Gi dissociation from the receptor. Indeed the Delta V-L mutation in EpoR, which disrupts Gi binding to EpoR, did not alter Jak2 phosphorylation by Epo and its binding to the receptor. Furthermore in 32D cells, we previously showed that Epo-induced Gi dissociation from the EpoR is not affected when the Jak2-deficient EpoR mutant is expressed (15). Therefore, Jak2 is more likely acting downstream of beta gamma release and upstream of Ras and PI3K. In addition to Jak2, the tyrosine kinases Syk and Lyn have been implicated in EpoR activation (39, 57), but their contribution to Gi-dependent MAPK activation remains to be determined.

Four documented pathways have been implicated in Epo-mediated regulation of the Erk cascade in various hematopoietic cell lines or erythroid progenitors expressing the EpoR. Three of them, the Shc/Grb2/Sos pathway (11), the Grb2/Sos pathway (32), and the CrkL/C3G pathway (33), lead to MAPK activation via Ras. The fourth one involves PI3K and might require an atypical protein kinase C (36). All these pathways are initiated through effector binding to phosphorylated tyrosines located in the intracellular domain of the receptor. Particularly, tyrosines 460 and 479 have been shown to be involved in CrkL/C3G and in PI3K-dependent Erk activation by the EpoR, respectively (36, 40), and tyrosine 464 has a consensus Grb2 binding motif (32). In CHO cells, MAPK activation by Epo is unlikely to occur through PI3K binding to tyrosine 479 since PI3K activation is inhibited by the beta gamma competitor beta ARK-ct. The region of the EpoR required for Gi binding in vivo and Gi-dependent MAPK phosphorylation by Epo (amino acids 469-475) does not include tyrosines. Thus, Gi-dependent Erk activation may involve a different mechanism. The possibility that the absence of Erk activation in the Delta V-L EpoR deleted of the Gi binding domain resulted from a conformational change affecting the nearby tyrosines is highly unlikely. Indeed Epo-induced CrkL and Grb2 interaction is preserved in the Delta V-L mutant. Furthermore, pertussis toxin and beta ARK-ct also inhibit Epo-induced MAPK activation.

In hematopoietic cells, Gi binds to the EpoR through the same EpoR domain required for Gi-dependent Erk activation in CHO cells, and Gi is activated and dissociates from the receptor after Epo stimulation (15). However, in these cells, pertussis toxin has little effect on Epo-dependent Erk activation. As described above, there are several different pathways leading to MAPK activation by Epo in hematopoietic cells. The Gi/PI3K/MAPK pathway may be only one of them, explaining the relative inefficiency of the toxin in such cells. The relative contribution of the different pathways leading to MAPK activation by the EpoR and their interconnections remain poorly documented and need to be explored further. In contrast with hematopoietic cells, the Gi-dependent pathway is the main pathway involved in Epo-dependent MAPK activation in CHO epithelial cells. Epo-induced EpoR tyrosine phosphorylation is lower in CHO than in hematopoietic cells.2 CHO cells may mainly use the Gi-dependent pathway because of the inefficiency of MAPK pathways initiated by phosphorylated tyrosines of the receptor.

In erythroid precursors Gi regulates an Epo-modulated Ca2+ channel (58, 59). This regulation is mediated by Galpha i2, and tyrosine 460 in EpoR is critical for Epo-stimulated Ca2+ influx in CHO and in Ba/F3 hematopoietic cells (60). Tyrosine 460 is not required for Gi interaction with the EpoR in vitro, and Gi-dependent Erk activation involves the beta gamma subunits of Gi. These data suggest that different Gi-dependent pathways lead to calcium (through alpha i2) and MAPK (through beta gamma ) activation by EpoR. Epo function in non-hematopoietic cells is not unique to epithelial cells. Indeed, myoblasts, neural cells, and endothelial cells have been shown to express EpoR (61-63). Epo has anti-apoptotic function in neural cells and in brain (64, 65) and is implicated in brain development and neurogenesis (66, 67). Epo has also been implicated in angiogenesis (68) and may regulate muscle cell proliferation and differentiation (62). Although the intracellular pathways activated by Epo in non-hematopoietic cells are still poorly documented, Epo was shown to activate MAPK and Jak2 in neural and in muscle cells (62, 65, 69). Further investigations would allow the determination of the function and contribution of the Gi-dependent pathway to MAPK activation pathway in hematopoietic and non-hematopoietic cells.

    ACKNOWLEDGEMENTS

We are grateful to Dr. A. Eychène for providing HA-RasN17 vector, Dr. J. Ihle for pXM/EpoR-W282R vector, and Dr. R. Jockers for the beta ARK-ct vector and for helpful discussions. We thank J. Garcia for advice with the use of HA-RasN17 vector and Dr. Sylvie Gisselbrecht for continuous support.

    FOOTNOTES

* This work was supported by grants from the Comité de Paris of the Ligue Nationale Contre le Cancer, associate laboratory No. 8.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Fax: 33-1-40-51-65-10; E-mail: duprez@cochin.inserm.fr.

Published, JBC Papers in Press, January 21, 2003, DOI 10.1074/jbc.M208834200

2 P. Mayeux, unpublished data.

    ABBREVIATIONS

The abbreviations used are: Epo, erythropoietin; EpoR, Epo receptor; MAPK, mitogen-activated protein kinase; Erk, extracellular signal-regulated kinase; PI3K, phosphoinositide 3-kinase; GPCR, seven transmembrane-spanning G protein-coupled receptor; G protein, heterotrimeric GTP-binding protein; PT, pertussis toxin; MalE, maltose-binding protein; MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase; CHO, Chinese hamster ovary; PMA, phorbol 12-myristate 13-acetate; HA, hemagglutinin; beta ARK1-ct, C-terminal fragment of the beta -adrenergic receptor kinase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Constantinescu, S. N., Ghaffari, S., and Lodish, H. F. (1999) Trends Endocrinol. Metab. 10, 18-23[CrossRef][Medline] [Order article via Infotrieve]
2. Miura, O., D'Andrea, A., Kabat, D., and Ihle, J. N. (1991) Mol. Cell. Biol. 11, 4895-4902[Medline] [Order article via Infotrieve]
3. Dusanter-Fourt, I., Casadevall, N., Lacombe, C., Muller, O., Billat, C., Fischer, S., and Mayeux, P. (1992) J. Biol. Chem. 267, 10670-10675[Abstract/Free Full Text]
4. Ihle, J. N. (1995) Nature 377, 591-594[CrossRef][Medline] [Order article via Infotrieve]
5. Damen, J. E., Mui, A. L. F., Puil, L., Pawson, T., and Krystal, G. (1993) Blood 81, 3204-3210[Abstract]
6. Miura, O., Nakamura, N., Ihle, J. N., and Aoki, N. (1994) J. Biol. Chem. 269, 614-620[Abstract/Free Full Text]
7. Mayeux, P., Dusanter-Fourt, I., Muller, O., Mauduit, P., Sabbah, M., Drucker, B., Vainchencker, W., Fischer, S., Lacombe, C., and Gisselbrecht, S. (1993) Eur. J. Biochem. 216, 821-828[Abstract]
8. Gobert, S., Chrétien, S., Gouilleux, F., Muller, O., Pallard, C., Dusanter-Fourt, I., Groner, B., Lacombe, C., Gisselbrecht, S., and Mayeux, P. (1996) EMBO J. 15, 2434-2441[Abstract]
9. Damen, J., Mui, A. L. F., Hughes, P., Humphries, K., and Krystal, G. (1992) Blood 80, 1923-1932[Abstract]
10. Torti, M., Marti, K. B., Altschuler, D., Yamamoto, K., and Lapetina, E. G. (1992) J. Biol. Chem. 267, 8293-8298[Abstract/Free Full Text]
11. Miura, Y., Muira, O., Ihle, J. N., and Aoki, N. (1994) J. Biol. Chem. 269, 29962-29969[Abstract/Free Full Text]
12. Gobert, S., Duprez, V., Lacombe, C., Gisselbrecht, S., and Mayeux, P. (1995) Eur. J. Biochem. 234, 75-83[Abstract]
13. Carroll, M. P., Spivak, J. L., McMahon, M., Weich, N., Rapp, U. R., and May, W. S. (1991) J. Biol. Chem. 266, 14964-14969[Abstract/Free Full Text]
14. Damen, J., and Krystal, G. (1996) Exp. Hematol. 24, 1455-1459[Medline] [Order article via Infotrieve]
15. Guillard, C., Chretien, S., Jockers, R., Fichelson, S., Mayeux, P., and Duprez, V. (2001) J. Biol. Chem. 276, 2007-2014[Abstract/Free Full Text]
16. Johnson, G. L., Gardner, A. M., Lange-Carter, C., Qian, N. X., Russell, M., and Winitz, S. (1994) J. Cell. Biochem. 54, 415-422[Medline] [Order article via Infotrieve]
17. Crespo, P., Xu, N., Simonds, W. F., and Gutkind, J. S. (1994) Nature 369, 418-420[CrossRef][Medline] [Order article via Infotrieve]
18. Faure, M., Voyno-Yasenetskaya, T. A., and Bourne, H. R. (1994) J. Biol. Chem. 269, 7851-7854[Abstract/Free Full Text]
19. van Biesen, T., Hawes, B. E., Luttrell, D. K., Krueger, K. M., Touhara, K., Porfiri, E., Sakaue, M., Luttrell, L. M., and Lefkowitz, R. J. (1995) Nature 376, 781-784[CrossRef][Medline] [Order article via Infotrieve]
20. Hu, Q., Klippel, A., Muslin, A. J., Fantl, W. J., and Williams, L. T. (1995) Science 268, 100-102[Medline] [Order article via Infotrieve]
21. Hawes, B. E., Luttrell, L. M., van Biesen, T., and Lefkowitz, R. J. (1996) J. Biol. Chem. 271, 12133-12136[Abstract/Free Full Text]
22. Lopez-Ilasaca, M., Crespo, P., Pellici, P. G., Gutkind, J. S., and Wetzker, R. (1997) Science 275, 394-397[Abstract/Free Full Text]
23. Bondeva, T., Pirola, L., Bulgarelli-Leva, G., Rubio, I., Wetzker, R., and Wymann, M. P. (1998) Science 282, 293-296[Abstract/Free Full Text]
24. Gupta, S. K., Gallego, C., Johnson, G. L., and Heasley, L. E. (1992) J. Biol. Chem. 267, 7987-7990[Abstract/Free Full Text]
25. Pace, A. M., Wong, Y. H., and Bourne, H. R. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 7031-7035[Abstract]
26. Jacobs-Helber, S. M., Ryan, J. J., and Sawyer, S. T. (2000) Blood 96, 933-940[Abstract/Free Full Text]
27. Nagata, Y., Takahashi, N., Davis, R. J., and Todokoro, K. (1998) Blood 92, 1859-1869[Abstract/Free Full Text]
28. Nagata, Y., and Todokoro, K. (1999) Blood 94, 853-863[Abstract/Free Full Text]
29. Cutler, R. L., Liu, L., Damen, J. E., and Krystal, G. (1993) J. Biol. Chem. 268, 21463-21465[Abstract/Free Full Text]
30. Damen, J., Liu, L., Cutler, R., and Krystal, G. (1993) Blood 82, 2296-2303[Abstract]
31. Tauchi, T., Feng, G., Shen, R., Hoatlin, M., Bagby, G. J., Kabat, D., Lu, L., and Broxmeyer, H. (1995) J. Biol. Chem. 270, 5631-5635[Abstract/Free Full Text]
32. Barber, D. L., Corless, C. N., Xia, K., Roberts, T. M., and D'Andrea, A. D. (1997) Blood 89, 55-64[Abstract/Free Full Text]
33. Nosaka, Y., Arai, A., Miyasaka, N., and Miura, O. (1999) J. Biol. Chem. 274, 30154-30162[Abstract/Free Full Text]
34. Arai, A., Kanda, E., and Miura, O. (2002) Oncogene 21, 2641-2651[CrossRef][Medline] [Order article via Infotrieve]
35. Devemy, E., Billat, C., and Haye, B. (1997) Cell Signal 9, 41-46[CrossRef][Medline] [Order article via Infotrieve]
36. Klingmuller, U., Wu, H., Hsiao, J. G., Toker, A., Duckworth, B. C., Cantley, L. C., and Lodish, H. F. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 3016-3021[Abstract/Free Full Text]
37. Mayeux, P., Lacombe, C., Casadevall, N., Chretien, S., Dusanter, I., and Gisselbrecht, S. (1991) J. Biol. Chem. 266, 23380-23385[Abstract/Free Full Text]
38. Koch, W. J., Hawes, B. E., Inglese, J., Luttrell, L. M., and Lefkowitz, R. J. (1994) J. Biol. Chem. 269, 6193-6197[Abstract/Free Full Text]
39. Duprez, V., Blank, U., Chretien, S., Gisselbrecht, S., and Mayeux, P. (1998) J. Biol. Chem. 273, 33985-33990[Abstract/Free Full Text]
40. Arai, A., Kanda, E., Nosaka, Y., Miyasaka, N., and Miura, O. (2001) J. Biol. Chem. 276, 33282-33290[Abstract/Free Full Text]
41. Burgering, B. M., Pronk, G. J., van Weeren, P. C., Chardin, P., and Bos, J. L. (1993) EMBO J. 12, 4211-4220[Abstract]
42. Koch, W. J., Hawes, B. E., Allen, L. F., and Lefkowitz, R. J. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 12706-12710[Abstract/Free Full Text]
43. Witthuhn, B., Quelle, F., Silvennoinen, O., Yi, T., Tang, B., Miura, O., and Ihle, J. (1993) Cell 74, 227-236[Medline] [Order article via Infotrieve]
44. Takeda, H., Matozaki, T., Takada, T., Noguchi, T., Yamao, T., Tsuda, M., Ochi, F., Fukunaga, K., Inagaki, K., and Kasuga, M. (1999) EMBO J. 18, 386-395[Abstract/Free Full Text]
45. Alblas, J., van Corven, E. J., Hordijk, P. L., Milligan, G., and Moolenaar, W. H. (1993) J. Biol. Chem. 268, 22235-22238[Abstract/Free Full Text]
46. Howe, L. R., and Marshall, C. J. (1993) J. Biol. Chem. 268, 20717-20720[Abstract/Free Full Text]
47. Hawes, B. E., van Biesen, T., Koch, W. J., Luttrell, L. M., and Lefkowitz, R. J. (1995) J. Biol. Chem. 270, 17148-17153[Abstract/Free Full Text]
48. Luttrell, L., van, B. T., Hawes, B., Koch, W., Touhara, K., and Lefkowitz, R. (1995) J. Biol. Chem. 270, 16495-16498[Abstract/Free Full Text]
49. Fedorov, Y., Jones, N., and Olwin, B. (1998) Mol. Cell. Biol. 18, 5780-5787[Abstract/Free Full Text]
50. Rakhit, S., Pyne, S., and Pyne, N. J. (2000) Mol. Pharmacol. 58, 413-420[Abstract/Free Full Text]
51. Conway, A. M., Rakhit, S., Pyne, S., and Pyne, N. J. (1999) Biochem. J. 337, 171-177[CrossRef][Medline] [Order article via Infotrieve]
52. Yart, A., Roche, S., Wetzker, R., Laffargue, M., Tonks, N., Mayeux, P., Chap, H., and Raynal, P. (2002) J. Biol. Chem. 277, 21167-21178[Abstract/Free Full Text]
53. Luttrell, L. M., Hawes, B. E., van Biesen, T., Luttrell, D. K., Lansing, T. J., and Lefkowitz, R. J. (1996) J. Biol. Chem. 271, 19443-19450[Abstract/Free Full Text]
54. Wan, Y., Kurosaki, T., and Huang, X. Y. (1996) Nature 380, 541-544[CrossRef][Medline] [Order article via Infotrieve]
55. Dikic, I., Tokiwa, G., Lev, S., Courtneidge, S. A., and Schlessinger, J. (1996) Nature 383, 547-550[CrossRef][Medline] [Order article via Infotrieve]
56. Daub, H., Weiss, F., Wallasch, C., and Ullrich, A. (1996) Nature 379, 557-560[CrossRef][Medline] [Order article via Infotrieve]
57. Tilbroook, P. A., Ingley, E., Williams, J. H., Hibbs, M. L., and Klinken, S. P. (1997) EMBO J. 16, 1610-1619[Abstract/Free Full Text]
58. Miller, B., Foster, K., Robishaw, J., Whitfield, C., Bell, L., and Cheung, J. (1991) Blood 77, 486-492[Abstract]
59. Miller, B., Bell, L., Hansen, C., Robishaw, J., Linder, M., and Cheung, J. (1996) J. Clin. Invest. 98, 1728-1736[Abstract/Free Full Text]
60. Miller, B., Barber, D., Bell, L., Beattie, B., Zhang, M., Neel, B., Yoakim, M., Rothblum, L., and Cheung, J. (1999) J. Biol. Chem. 274, 20465-60472[Abstract/Free Full Text]
61. Digicaylioglu, M., Bichet, S., Marti, H. H., Wenger, R. H., Rivas, L. A., Bauer, C., and Gassmann, M. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 3717-3720[Abstract/Free Full Text]
62. Ogilvie, M., Yu, X., Nicolas-Metral, V., Pulido, S. M., Liu, C., Ruegg, U. T., and Noguchi, C. T. (2000) J. Biol. Chem. 275, 39754-39761[Abstract/Free Full Text]
63. Masuda, S., Nagao, M., Takahata, K., Konishi, Y., Gallyas, F. J., Tabira, T., and Sasaki, R. (1993) J. Biol. Chem. 268, 11208-11216[Abstract/Free Full Text]
64. Sakanaka, M., Wen, T. C., Matsuda, S., Masuda, S., Morishita, E., Nagao, M., and Sasaki, R. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 4635-4640[Abstract/Free Full Text]
65. Siren, A. L., Fratelli, M., Brines, M., Goemans, C., Casagrande, S., Lewczuk, P., Keenan, S., Gleiter, C., Pasquali, C., Capobianco, A., Mennini, T., Heumann, R., Cerami, A., Ehrenreich, H., and Ghezzi, P. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 4044-4049[Abstract/Free Full Text]
66. Shingo, T., Sorokan, S. T., Shimazaki, T., and Weiss, S. (2001) J. Neurosci. 21, 9733-9743[Abstract/Free Full Text]
67. Yu, X., Shacka, J. J., Eells, J. B., Suarez-Quian, C., Przygodzki, R. M., Beleslin-Cokic, B., Lin, C. S., Nikodem, V. M., Hempstead, B., Flanders, K. C., Costantini, F., and Noguchi, C. T. (2002) Development 129, 505-516[Medline] [Order article via Infotrieve]
68. Ribatti, D., Presta, M., Vacca, A., Ria, R., Giuliani, R., Dell'Era, P., Nico, B., Roncali, L., and Dammacco, F. (1999) Blood 93, 2627-2636[Abstract/Free Full Text]
69. Digicaylioglu, M., and Lipton, S. A. (2001) Nature 412, 641-647[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.